Renascience Inc.
4889.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.22B
Close$
Share Statistics
| Market cap | $14.22 Billion |
|---|---|
| Enterprise Value | $11.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.39 |
| Beta | 1.68 |
| Outstanding Shares | 13,776,890 |
Return
| Return on Equity | -9.76% |
|---|---|
| Return on Assets | -9.61% |
| Return on Invested Capital | -10.34% |
Valuation & Multiples
| P/E Ratio | -42.86 |
|---|---|
| PEG | -189.02 |
| Price to Sales | 258.0 |
| Price to Book Ratio | 4.39 |
| Enterprise Value to Revenue | 160.65 |
| Enterprise Value to EBIT | -32.86 |
| Enterprise Value to Net Income | -35 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Renascience Inc.
3 employees
CEO: Toshio Miyata Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor tha...